Inhaled Sedation in Acute Respiratory Distress Syndrome
Authors:
Top Cited Papers
- 13 May 2025
- journal article
- Published by American Medical Association (AMA) in JAMA
- Vol. 333 (18) , 1608
Abstract
Importance: Whether the use of inhaled or intravenous sedation affects outcomes differentially in mechanically ventilated adults with acute respiratory distress syndrome (ARDS) is unknown.Objective: To determine the efficacy and safety of inhaled sevoflurane compared with intravenous propofol for sedation in patients with ARDS.Design, Setting, and Participants: Phase 3 randomized, open-label, assessor-blinded clinical trial conducted from May 2020 to October 2023 with 90-day follow-up. Adults with early moderate to severe ARDS (defined by a ratio of Pao2 to the fraction of inspired oxygen of 2O) were enrolled in 37 French intensive care units.Interventions: Patients were randomized to a strategy of inhaled sedation with sevoflurane (intervention group) or to a strategy of intravenous sedation with propofol (control group) for up to 7 days.Main Outcomes and Measures: The primary end point was the number of ventilator-free days at 28 days; the key secondary end point was 90-day survival.Results: Of 687 patients enrolled (mean [SD] age, 65 [12] years; 30% female), 346 were randomized to sevoflurane and 341 to propofol. The median total duration of sedation was 7 days (IQR, 4 to 7) in both groups. The number of ventilator-free days through day 28 was 0.0 days (IQR, 0.0 to 11.9) in the sevoflurane group and 0.0 days (IQR, 0.0 to 18.7) in the propofol group (median difference, −2.1 [95% CI, −3.6 to −0.7]; standardized hazard ratio, 0.76 [95% CI, 0.50 to 0.97]). The 90-day survival rates were 47.1% and 55.7% in the sevoflurane and propofol groups, respectively (hazard ratio, 1.31 [95% CI, 1.05 to 1.62]). Among 4 secondary outcomes, sevoflurane was associated with higher 7-day mortality (19.4% vs 13.5%, respectively; relative risk, 1.44 [95% CI, 1.02 to 2.03]) and fewer intensive care unit–free days through day 28 (median, 0.0 [IQR, 0.0 to 6.0] vs 0.0 [IQR, 0.0 to 15.0]; median difference, –2.5 [95% CI, –3.7 to –1.4]) compared with propofol.Conclusions and Relevance: Among patients with moderate to severe ARDS, inhaled sedation with sevoflurane resulted in fewer ventilator-free days at day 28 and lower 90-day survival than sedation with propofol.Trial Registration: ClinicalTrials.gov Identifier: NCT04235608Keywords
This publication has 37 references indexed in Scilit:
- Sedation in the ICUNEJM Evidence, 2024
- Renal safety of critical care sedation with sevoflurane: a systematic review and meta-analysisJournal of Anesthesia, 2023
- ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategiesIntensive Care Medicine, 2023
- Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trialThe Lancet Respiratory Medicine, 2021
- Analgesia and sedation in patients with ARDSIntensive Care Medicine, 2020
- Early Neuromuscular Blockade in the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2019
- Effect of Titrating Positive End-Expiratory Pressure (PEEP) With an Esophageal Pressure–Guided Strategy vs an Empirical High PEEP-Fio2 Strategy on Death and Days Free From Mechanical Ventilation Among Patients With Acute Respiratory Distress SyndromeJAMA, 2019
- Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 CountriesJAMA, 2016
- Prone Positioning in Severe Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2013
- Summary of Recommendation StatementsKidney International Supplements, 2012